Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease

Neuroscience Bulletin

Volumn 29, Issue 5, 2013, Pages 661-669

  Lv, Qing ^a   Zhang, Baorong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

application; continuous dopaminergic stimulation; L dopa induced dyskinesias; Parkinson's disease

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CARBOXYMETHYLCELLULOSE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROTIGOTINE;

BASAL GANGLION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); DAYTIME SOMNOLENCE; DERMATITIS; DIARRHEA; DISEASE MODEL; DIZZINESS; DOPAMINERGIC NERVE CELL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DYSKINESIA; FATIGUE; HUMAN; INJECTION SITE REACTION; MENTAL DISEASE; NAUSEA; NERVE CELL STIMULATION; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPERTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN MANIFESTATION; SKIN NODULE; STEADY STATE; STRIATE CORTEX; SUBSTANTIA NIGRA PARS COMPACTA; SUSTAINED RELEASE FORMULATION; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84885305873     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-013-1329-8     Document Type: Review

References (56)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan BM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68(5): 384-386.
2. Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004, 55: 41-60.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16(3): 448-458.
4. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005, 26(8): 391-397.
5. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinsons disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001, 19(10): 1013-1038.
6. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5(8): 677-687.
7. Rascol O. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Eur J Neurol 2011, 18(Suppl 1): 3-10.
8. Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41(1): 1-24.
9. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where and what. Mov Disord 2000, 15(1): 3-8.
10. Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(3): 68-71.
11. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N. Increased D1 dopamine receptor signaling in levodopainduced dyskinesia. Ann Neurol 2005, 57(1): 17-26.
12. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002, 61(2): 186-196.
13. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bédard PJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 1997, 49(1-2): 55-62.
14. Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006, 59(1): 64-74.
15. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003, 183(2): 458-468.
16. Wolters EC. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007, 13(Suppl): 18-23.
17. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-Label, randomized, phase I multiple dose studies. Clin Ther 2012, 34(4): 966-978.
18. Eisenreich W, Sommer B, Hartter S, Jost WH. Pramipexole extended release: a novel treatment option in Parkinson's disease. Parkinsons Dis 2010, 2010: 1-7.
19. García Ruiz PJ, Sesar Ignacio Á, Ares Pensado B, Castro García A, Alonso Frech F, Álvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord 2008, 23(8): 1130-1136.
20. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009, 24(10): 1468-1474.
21. Sethi KD, Hauser RA, Isaacson SH, McClain T. Levodopa/ carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: a case series. Cases J 2009, 2(1): 7134.
22. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005, 65(2 Suppl 1): 3-5.
23. Schmidt WJ, Lebsanft H, Heindl M, Gerlach M, Gruenblatt E, Riederer P, et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats contralateral rotations and abnormal involuntary movements. Neural Transm 2008, 115(10): 1385-1392.
24. Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 2009, 219(2): 533-542.
25. Jenner P, McCreary AC, Scheller DK. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011, 118(12): 1691-1702.
26. Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study. Parkinsonism Relat Disord 2012, 18(5): 488-493.
27. Domino EF, Ni L, Zhang H, Kohno Y, Sasa M. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. Eur J Pharmacol 1997, 325(2-3): 137-144.
28. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011, 77(8): 767-774.
29. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010, 25(15): 2542-2549.
30. Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, et al. Efficacy, safety, and tolerability of overnight switching from immediate-to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord 2010, 25(14): 2326-2332.
31. Battaglia G, Busceti CL, Cuomo L, Giorgi FS, Orzi F, De Blasi A, et al. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology 2002, 42(3): 367-373.
32. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov Disord 2005, 20(2): 151-157.
33. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975, 25(12): 1144-1148.
34. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982, 2(8295): 412-415.
35. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64(2): 216-223.
36. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24(7): 993-1000.
37. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994, 44(5): 913-919.
38. Marin C, Aguilar E, Obeso JA. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov Disord 2006, 21(5): 646-653.
39. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005, 20(3): 306-314.
40. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/ carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009, 24(4): 541-550.
41. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol 2010, 68(1): 18-27.
42. Braun M, Cawello W, Poole K. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005, 12(Suppl 2): 37.
43. Kehr J, Scheller DKA. Continuous delivery of rotigotine leads to continuous dopamine receptor stimulation in a rat model. Eur J Neurol 2005, 12: 37.
44. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22(16): 2398-2404.
45. Schnitzler A, Leffers KW, Häck HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010, 16(8): 513-516.
46. Antonini A TE, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8(10): 929-937.
47. Espay AJ. Management of motor complications in Parkinson disease: current and emerging therapies. Neurol Clin 2010, 28(4): 913-925.
48. Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2010, 118(6): 907-914.
49. Trugman JM, Hubbard CA, Bennett JP Jr. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res 1996, 725(2): 177-183.
50. Stoessl AJ. Continuous Dopaminergic Therapy in Parkinson disease time to stride back. Ann Neurol 2010, 68(1): 3-5.
51. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transder mal rotigotine in advanced Parkinson's disease a doubleblind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6(6): 513-520.
52. Antonini A. Continuous dopaminergic stimulation-from theory to clinical practice. Parkinsonism Relat Disord 2007, 13: S24-28.
53. Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008, 31(3): 151-166.
54. Gancher ST, Woodward WR, Nutt JG. Apomorphine tolerance in Parkinson's disease: lack of a dose effect. Clin Neuropharmacol 1996, 19(1): 59-64.
55. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010, 25(15): 2542-2549.
56. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with parkinson disease: long-term results. Neurol Sci 2001, 22(1): 93-94.